French singer Nicole Croisille, of 'A Man and a Woman' fame, dies at 88
PARIS: Nicole Croisille, a French singer who sang on the soundtrack of the hit 1966 film "A Man and a Woman", has died, her agent told AFP on Wednesday. She was 88.
Croisille died "following a long illness" in Paris during the night of Tuesday-Wednesday, Jacques Metges said.
"Until the end, she fought with lots of force and courage," he added.
Croisille was best known internationally for her work on the film soundtrack of "A Man and a Woman", including the solo "Today it's You" and several duets.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
10 hours ago
- Time of India
Ireland probes mistreatment at care homes run by French company
Representative AI image DUBLIN: Ireland's health ministry Thursday ordered a probe into French care homes operator Emeis, the country's biggest private nursing home provider, after a television programme alleged residents in two places were mistreated. The investigative programme aired undercover footage of elderly residents allegedly forced into chairs, and being ignored when they pleaded for help to go to the toilet. The programme, shown on Irish state broadcaster RTE on Wednesday, also showed some residents were left in incontinence pads for so long their clothes were soaked. The scenes were "extremely distressing" and "wholly unacceptable", health ministry official Kieran O'Donnell told RTE Thursday. The ministry has ordered the Health Information and Quality Authority (HIQA) to launch a review of all nursing homes operated by Emeis, he said. Offering its "sincere apologies", the firm said "this is not the standard of care it expects and not what residents and their families deserve", and pledged to review all operations across Ireland. Emeis, which was called Orpea until last year, run 27 private nursing homes in Ireland. The company entered the Irish market in 2020 through the takeover of another portfolio. HIQA, who are tasked with inspecting care homes, said Emeis-run homes including the two featured in Wednesday's programme had triggered recent concerns. Earlier this year, HIQA ordered one of them to cease admitting new residents, citing "significant concerns". Minister for Enterprise Peter Burke told RTE an institution should not be operating "if people are not being cared for appropriately, with dignity, with respect". "HIQA need to really enforce that and to ensure that everyone has a basic level of dignity and care that they deserve in their twilight years," said Burke. Emeis changed its name to turn the page on a scandal in France when its homes came under scrutiny following the 2022 publication of the book "The Gravediggers" by independent journalist Victor Castan. It cited employees and relatives claiming that residents were at times left for hours with soiled underwear or went days without care as managers sought to maximise profit margins. Orpea contested those claims as "untruthful, scandalous and injurious".
Business Standard
14 hours ago
- Business Standard
Servier India introduces 'Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
VMPL Mumbai (Maharashtra) [India], June 5: Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication. Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30-40% of AML patients in India receive adequate treatment1, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature they are usually diagnosed when the disease is advanced.2 The announcement marks a significant advancement in management of the mentioned rare and difficult-to-treat cancers in India, addressing a critical unmet medical need. Speaking on the occasion, Mr. Aurelien Breton, Managing Director, Servier India, said, "Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most. By prioritizing access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch is a significant step forward in our mission to support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India." IDH1 mutation occurs in approximately 7-14% of AML patients in India3, making targeted mechanisms especially relevant for this subset. "This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and advancing cancer care in India.", highlighted Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India. Speaking on the importance of treatment access, Ms. Pratima Tripathi, Commercial Director, Servier India, said: "Our foremost priority is to ensure that the therapy is accessible and affordable to patients across India. We are actively collaborating with healthcare providers, patient advocacy groups, and policymakers to remove barriers and facilitate timely access to this important therapy. Through these partnerships, we are committed to expanding treatment options and making a meaningful difference in the lives of patients." By introducing these advanced therapies, Servier India reaffirms its commitment to advancing innovative cancer treatments that improve clinical outcomes and enhance the quality of life of patients. Disclaimer: This press release is intended solely to share regulatory and medical information regarding the launch; the reference to "Tibsovo" is not intended as a promotional or public advertisement. Use of the therapy is strictly based on a doctor's prescription and clinical discretion. About Servier India Servier India has been committed for over three decades to delivering innovative pharmaceutical solutions that improve the lives of patients and their families across India. Established in 1985 as an affiliate of the leading independent French pharmaceutical Servier Group, the company focuses on therapeutic areas such as Cardiometabolism, Neuroscience, Venous Diseases, and Oncology. Servier India has a strong pan-India presence and a dedicated workforce of around 580 that strives to address critical healthcare challenges with passion and purpose. As part of Servier group operating in over 150 countries, Servier India inherits a rich legacy of scientific excellence and patient-centric innovation. Globally, Servier invests heavily in research and development, focusing on our key therapeutic areas. About Servier Servier is a global pharmaceutical group governed by a Foundation that aspires to serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. As a world leader in cardiometabolism and venous diseases, Servier's ambition is to become a focused and innovative player in oncology by targeting rare cancers. Headquartered in France, Servier relies on a strong geographical footprint; its medicines are available in close to 140 group achieved a revenue of EUR5.9 billion in 2024. Additional Details on Ivosidenib Internationally, Ivosidenib has already received regulatory approvals in more than 42 countries, including the USA, Europe, China, UAE, and South Korea. In the United States, the US FDA approved it in 2019 as a monotherapy and later in May 2022 as a combination treatment with Azacitidine for patients aged 75 and above, or those who cannot tolerate intensive chemotherapy. The European Medical Agency (EMA) gave its approval in May 2023 for use in patients who are not fit for standard induction chemotherapy. In India, the process moved forward in April 2025, when the Subject Expert Committee (SEC) gave a positive recommendation for Ivosidenib. Following this, the DCGI granted approval for the marketing authorization in May 2025
&w=3840&q=100)
First Post
16 hours ago
- First Post
Why is Greta Thunberg sailing towards Gaza?
Greta Thunberg, along with a group of climate activists including French MP Rima Hassan and Game of Thrones actor Liam Cunningham, is sailing to Gaza on the 'Madleen', a boat operated by the Freedom Flotilla Coalition. The vessel is carrying humanitarian supplies as a protest against Israel's war on Gaza and its blockade of aid. The Israel Defense Forces (IDF) are watching closely read more Thunberg is heading to Gaza on a humanitarian ship. Instagram/gretathunberg Greta Thunberg and a group of climate activists are sailing towards Gaza in an attempt to 'break Israel's siege' on the region. They are travelling on the Madleen, a boat operated by the Freedom Flotilla Coalition, which left the southern Italian port of Catania last week. Rima Hassan, who is a member of the European Parliament, is also on board. The boat is carrying humanitarian supplies. ALSO READ | A new aid delivery system has started in Gaza. Why is it causing controversy? STORY CONTINUES BELOW THIS AD Although aid has started to reach Gaza again in small amounts, relief groups say the situation remains critical and people are at risk of severe hunger. Now, Israel has responded to Thunberg's action, saying it will take steps as needed. Why is Greta Thunberg sailing to Gaza? Who else is on the boat with her? And how has Israel reacted? Let's answer these questions for you. Why is Greta Thunberg headed to Gaza? Who else is on the trip? Thunberg is heading to Gaza on a humanitarian ship to protest against Israel's war on the territory and its blockade on aid. The journey is organised by the Freedom Flotilla, a coalition of groups opposing the blockade Israel imposed on Gaza on March 2, which has only recently started to ease. Alongside Thunberg, European Parliament member Rima Hassan is also on the trip. Hassan said the mission has 'several aims: to condemn the humanitarian blockade and ongoing genocide, the impunity granted to the state of Israel and raise international awareness'. Hassan, known for her outspoken views with the French left-wing party LFI, was previously denied entry to Israel when she planned to visit the occupied Palestinian territories with a European Parliament delegation. STORY CONTINUES BELOW THIS AD The voyage includes 12 international activists, among them Thunberg and actor Liam Cunningham from Game of Thrones. Thunberg was supposed to travel earlier this month on a similar ship, but it was damaged before reaching Gaza. Throughout the trip, Thunberg has shared videos showing her wrapped in a keffiyeh, holding a Palestinian flag, and swimming in the Mediterranean. Madleen will reach Gaza's shores with humanitarian aid and aims to draw attention to the ongoing crisis. Thunberg said, 'We are doing this because, no matter what odds we are against, we have to keep trying,' becoming emotional during her speech. STORY CONTINUES BELOW THIS AD Some activists on board reported that the boat was followed by drones, likely operated by the Greek coast guard. Gaza has faced a total blockade by Israel for over 90 days, with land, sea, and air restrictions since 2007. The aid on board includes milk, protein bars, baby formula, diapers, flour, rice, water filters, hygiene products, and medical supplies. What is Israel's plan? On Wednesday, Israel said that it is 'prepared' to 'act accordingly' to prevent Greta Thunberg from reaching Gaza. The Israel Defense Forces (IDF) confirmed that they are closely monitoring the flotilla. 'For this case as well, we are prepared,' IDF spokesman Brigadier General Effie Defrin told the Times of London. Greta Thunberg and a group of climate activists are sailing towards Gaza. AP 'We have gained experience in recent years, and we will act accordingly.' Defrin did not provide details on what measures might be taken. However, last month, an earlier Freedom Flotilla Coalition ship was damaged just before arriving in Malta to pick up Thunberg for a similar mission. The group accused Israel of using drones to attack the vessel. What's happening in Gaza? The United Nations said on Friday that the situation in Gaza is the worst since the conflict between Israel and Hamas militants began 19 months ago, even though limited aid has started to arrive in the area again. Facing growing international pressure, Israel lifted an 11-week blockade on Gaza, allowing some UN-led aid operations to resume. STORY CONTINUES BELOW THIS AD The Israeli government had said that the blockade aims to pressure Hamas into releasing hostages taken during the October 7, 2023, attack that led to the war. On that day, Hamas militants attacked southern Israel, killing about 1,200 people, mostly civilians, and abducting 251 hostages. Hamas still holds 58 hostages, with 23 believed to be alive. In response, Israel launched a military offensive that has killed more than 52,000 Palestinians, mostly women and children, according to Gaza's Health Ministry. Israeli bombardment and ground operations have devastated large parts of Gaza and left most of its population homeless. The Freedom Flotilla group is one of many critics accusing Israel of genocide in its war on Gaza. Israel strongly rejects these claims, insisting its actions target Hamas militants, not civilians. On Thursday, the White House said Israel had 'signed off' on a new ceasefire plan proposed by US President Donald Trump, but Hamas said it could not accept the deal. STORY CONTINUES BELOW THIS AD With inputs from agencies
